{"preliminary_commentary":{"by_channel":{"x_thread":25,"podcast":11,"youtube":9},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04663997\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-11-02T17:27:41.798Z","note":"Automated from the 40 newest of 45 indexed sources (Jun 2024 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":40,"text":"- Whether docetaxel or lutetium PSMA should come first\n- How to interpret overall survival alongside radiographic progression-free survival\n- How crossover affects interpretation of overall survival\n- Which patient features should guide treatment selection\n\nAlso discussed: patient-reported quality of life."},"drugs_tested":[["177Lu-PSMA-617"]],"indication":"PSMA-positive metastatic castration-resistant prostate cancer","name":"NCT04663997","nct_id":"NCT04663997","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04663997. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"177 Lu-PSMA-617","type":"EXPERIMENTAL"},{"description":null,"label":"Docetaxel","type":"ACTIVE_COMPARATOR"}],"collaborators":["Prostate Cancer Canada","Novartis Pharmaceuticals"],"completion_date":{"date":"2026-12-31","type":"ESTIMATED"},"conditions":["Prostate Cancer"],"enrollment":{"count":200,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"177Lu-PSMA-617","otherNames":[],"type":"DRUG"},{"name":"Docetaxel","otherNames":[],"type":"DRUG"}],"last_update":"2026-03-27","lead_sponsor":"Canadian Cancer Trials Group","official_title":"A Randomized Phase II Study of 177 LuPSMA-617 vs Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2025-08-25","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free survival","timeFrame":"3 years"}],"references":[],"start_date":{"date":"2021-08-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT04663997"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04663997"}